CHAPTER 2

HEPATITIS C IN AUSTRALIA

2.1 This Chapter provides a brief overview of hepatitis and the understanding of blood and blood safety in developed countries, paying particular attention to improvements in diagnostic technology in relation to hepatitis C. It also examines Australia's self-sufficiency in blood stocks, and outlines the factors underlying the increased risk of hepatitis faced by haemophiliacs. The timeline in Table 2.1 outlines the major events in the identification of hepatitis C and the development of tests to detect the virus in blood. The events listed are expanded upon in the remainder of the chapter.

Table 2.1: Timeline of history relating to hepatitis C

<table>
<thead>
<tr>
<th>Australia</th>
<th>Date</th>
<th>International</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1942</td>
<td>'Serum hepatitis' noted in Second World War</td>
</tr>
<tr>
<td></td>
<td>1947</td>
<td>Two types of hepatitis described</td>
</tr>
<tr>
<td></td>
<td>1965</td>
<td>Discovery of hepatitis B surface antigen</td>
</tr>
<tr>
<td>Red Cross starts screening for HBV</td>
<td>July</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1971</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1973</td>
<td>Hepatitis A virus discovered</td>
</tr>
<tr>
<td></td>
<td>1975</td>
<td>Non-A, non-B hepatitis described</td>
</tr>
<tr>
<td>Start of first Australian post-transfusion study (published in 1982)</td>
<td>1979</td>
<td></td>
</tr>
<tr>
<td></td>
<td>April</td>
<td>US Transfusion Transmitted Viruses (TTV) study predicts ALT testing would reduce the incidence of post-transfusion NANBH</td>
</tr>
<tr>
<td></td>
<td>1981</td>
<td></td>
</tr>
<tr>
<td></td>
<td>August</td>
<td>US National Institutes of Health study predicts that ALT testing would reduce the incidence of NANBH</td>
</tr>
<tr>
<td></td>
<td>1981</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nov</td>
<td>Canadian Red Cross Blood Transfusion Service advisory committee decides that</td>
</tr>
<tr>
<td></td>
<td>1981</td>
<td></td>
</tr>
</tbody>
</table>


2 The information in this timeline is based on the Krever Commission, Vol. 2; Submissions 54 (DoHA); 61 (AAPA); 64 (ARCBS).
<table>
<thead>
<tr>
<th>Event Description</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT testing should not be implemented as surrogate testing for NANBH</td>
<td>Jan 1982</td>
</tr>
<tr>
<td>Post-transfusion study of cardiac patients by Prof Cossart establishes risk of NANBH through blood supply at 1.7%</td>
<td>March 1983</td>
</tr>
<tr>
<td>ALT screening considered by US FDA, but no recommendation made.</td>
<td>1983</td>
</tr>
<tr>
<td>Committee of the American Association of Blood Banks rejects implementation of ALT testing. Even so, some blood banks introduce testing.</td>
<td>1983</td>
</tr>
<tr>
<td>Red Cross adds questions concerning high-risk sexual and injection behaviour to donor screening</td>
<td>1984</td>
</tr>
<tr>
<td>First case of transfusion related AIDS; introduction of uniform donor declaration by Red Cross</td>
<td>July 1984</td>
</tr>
<tr>
<td>Surrogate testing using anti-HBc for AIDS commenced in NSW</td>
<td>Oct 1984</td>
</tr>
<tr>
<td>Heat-treated Factor VIII developed by Australian Red Cross</td>
<td>Nov 1984</td>
</tr>
<tr>
<td>US TTV study predicts that anti-HBc testing would reduce incidence of post-transfusion NANBH</td>
<td>Dec 1984</td>
</tr>
<tr>
<td>Introduction of HIV Ab testing</td>
<td>1985</td>
</tr>
<tr>
<td>Preliminary data from the Toronto incidence study show the incidence on NANBH to be 7.6 per cent</td>
<td>May 1985</td>
</tr>
<tr>
<td>Majority of US fractionators begin to use ALT-tested plasma to manufacture blood products</td>
<td>July 1985</td>
</tr>
<tr>
<td>US FDA Blood Products Advisory Committee recommends that all blood donations for transfusion be tested for both ALT and anti-HBc as surrogate tests for NANBH</td>
<td>Nov 1985</td>
</tr>
<tr>
<td>American Association of Blood Banks and American Red Cross issue a joint statement recommending that blood collection agencies implement surrogate testing</td>
<td>Feb 1986</td>
</tr>
<tr>
<td>American Association of Blood Banks</td>
<td>March 1986</td>
</tr>
<tr>
<td></td>
<td>April</td>
</tr>
</tbody>
</table>
1986 | board of directors decide that both ALT and anti-HBc testing of blood donations should be implemented. Report of results from National Institutes of Health study predicting that anti-HBc would reduce incidence of post-transfusion NANBH Canadian Red Cross Blood Transfusion Service advisory committee recommends against surrogate testing for NANBH, pending further study of data from Toronto incidence study and of the efficacy of HIV-antibody testing as a surrogate test for NANBH

Nov 1986 | Target date for introduction of dual ALT and anti-HBc testing in majority of US blood banks, even though testing not required by FDA.

Start of second post-transfusion hepatitis study (published in 1995); National Blood Transfusion Committee does not support routine surrogate testing | 1987

Queensland Blood Transfusion Service begins surrogate testing | July 1987

Report on ALT surrogate testing published in Queensland, *Pathology* | 1988

May 1988 | Identification of HCV announced

BTS Executive Subcommittee agreed to start testing for HCV antibody as soon as practicable | Dec 1989

Hepatitis C becomes notifiable infection in States and Territories | 1990

Screening test for hepatitis C licensed in US | Jan 1990

Super heat treated Factor VIII available | Feb 1990

All transfusion services had commenced screening for anti-HCV | June 1990

Agreement between CSL and NBTC not to use anti-HCV repeat reactive plasma in the manufacture of plasma products | March 1991

US FDA requires anti-HBc testing of blood donations to identify units contaminated with HBV
<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Second generation kit introduced</td>
<td>May 1991</td>
<td>May 1991</td>
</tr>
<tr>
<td>Canadian Red Cross implements second generation HCV antibody testing</td>
<td>1992</td>
<td>throughout Canada</td>
</tr>
<tr>
<td>NSW BTS reported that only 30.8 per cent of donations found repeat</td>
<td>August 1992</td>
<td>reactive on anti-HCV screening were positive on confirmatory testing</td>
</tr>
<tr>
<td>Super heat treated Prothrombinex becomes available</td>
<td>1993</td>
<td></td>
</tr>
<tr>
<td>Report on risk of post-tranfusion/operative NANBH in Australia</td>
<td>July 1995</td>
<td>immediately before introduction of screening; concluded 1st generation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>anti-HCV test detected about 85 per cent of infective donations; and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>surrogate testing offered no additional advantage</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medical Journal of Australia</td>
</tr>
<tr>
<td>Australian Red Cross Blood Service established</td>
<td>1996</td>
<td></td>
</tr>
<tr>
<td>Krever Commission report released in Canada</td>
<td>Nov 1997</td>
<td></td>
</tr>
<tr>
<td>Regulation of fresh blood products commenced under the Therapeutic</td>
<td>2000</td>
<td></td>
</tr>
<tr>
<td>Good Goods Act 1989</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Introduction of Nucleic Acid Testing for HCV</td>
<td>June 2000</td>
<td></td>
</tr>
<tr>
<td>National Blood Authority established</td>
<td>2003</td>
<td></td>
</tr>
</tbody>
</table>

### History and nature of Hepatitis C

2.2 'Hepatitis' means inflammation of the liver. It can result from overuse of alcohol, reaction to certain medications or infection by bacteria or viruses. There are several different viruses that cause hepatitis, such as hepatitis A (HAV), hepatitis B (HBV) or hepatitis C (HCV). Each of these viruses may produce similar symptoms and they can all infect and inflame the liver. The main difference between the viruses is the mode of transmission, the way they cause liver damage and the effect each has on a person's health.³

2.3 Hepatitis C infection can be either acute, characterised by a short-lasting illness, or chronic, where hepatitis is present for six months or more. Those with acute HCV are commonly asymptomatic and may experience a mild flu-like illness. Some people, between 15 and 45 per cent (the higher proportion being in children), will clear themselves of the virus within four to six weeks of infection. In the remainder, chronic HCV infection occurs and causes the liver disease, chronic hepatitis C. Most people with chronic HCV show few, if any, outwardly visible symptoms. For this reason, many do not know they are infected. The symptoms that may be evident are often general, and include fatigue, lethargy, nausea and abdominal discomfort. The degree to which these symptoms may occur can vary significantly.

2.4 During the acute phase, levels of the virus in the blood rise dramatically until the body's immune response starts producing antibodies in an attempt to destroy the virus. In many cases, the virus successfully tricks the body into producing a poor antibody response. The infection is not brought under control properly by the body and the infection becomes chronic.

2.5 The importance of HCV infection lies in its persistence (or chronicity) and the liver disease it causes. Once a person is chronically infected, the virus is almost never cleared without treatment. In rare cases, HCV infection can even cause liver failure. However, most instances of acute infection are clinically undetectable.

2.6 The natural history of chronic HCV infection can vary dramatically between individuals. Some will have clinically insignificant or minimal liver disease and never develop complications. Others will have clinically apparent, chronic hepatitis. Cirrhosis may develop in about 20 per cent of individuals with HCV. This generally occurs at least 20 years after infection. Some patients with cirrhosis will develop end-stage liver disease. A proportion of individuals with cirrhosis resulting from HCV will also develop hepatocellular carcinoma (primary liver cancer).

2.7 For patients with chronic HCV, it is difficult to predict who will have a relatively benign course and who will go on to develop cirrhosis or cancer. Factors promoting progression of HCV-related chronic liver disease include viral genotype, age and sex of the person infected, alcohol abuse and whether the person is co-infected with another virus. Certain findings on liver biopsy can help in predicting the course of the disease.

2.8 The Barraclough Report noted that, based on studies of HCV infection acquired through routes other than the receipt of contaminated blood or blood products, it has been estimated that of all people with HCV antibodies, around 8 per cent would develop cirrhosis after 20 years following exposure, and 20 per cent would do so after 40 years. Rates of progression to liver cancer were more uncertain, but were about 10 per cent of the rate of progression to cirrhosis. Rates of progression to

---

cirrhosis in people infected with HCV from a blood transfusion are also generally much higher, as are rates of progression to cirrhosis in people with established chronic liver disease.\(^5\) Progress of the disease is also discussed in Chapter three.

2.9 The public health impact of hepatitis C infection is substantial and the socioeconomic costs to the Australian community are high. HCV also exacts a high personal cost on sufferers as it has a long term impact on quality of life. Further information on living with HCV is contained in Chapter five.

**Hepatitis C epidemiology\(^6\)**

2.10 Hepatitis C is the most frequently reported notifiable infection in Australia. It is estimated to affect about one per cent of the population, or 150,000 to 200,000 Australians, with an estimated incidence of 8,000 to 10,000 new infections occurring each year. This compares to HIV with an estimated prevalence\(^7\) of 15,900 cases and an incidence of 600 new cases per year.

2.11 The reported number of diagnoses of HCV infection has declined from a peak of 20,465 in 2000 to 15,953 cases in 2002. The reported number of diagnoses of newly acquired infection has declined from 672 cases in 2001 to 434 cases in 2002.

2.12 An estimated 225,000 people were living with hepatitis C infection in Australia in 2002. This includes 133,000 with chronic HCV and early liver disease (stage 0/1), 29,000 with chronic infection and moderate liver disease (stage 2/3) and 6,900 living with HCV-related cirrhosis. An estimated 57,000 had hepatitis C antibodies without chronic infection.

2.13 However, it is likely that many people with hepatitis C remain undiagnosed. It is estimated that 210,000 people in Australia have been exposed to the hepatitis C virus, of whom approximately 90,000 people live in NSW. Approximately 40 per cent of people in NSW who have been exposed to HCV are unaware of their status.

2.14 The main mode of transmission of hepatitis C in Australia is through unsafe drug injecting practices, in particular, the sharing and re-using of injecting equipment. Approximately 80 per cent of infections are attributed to the behaviour associated with injecting drug use, another 5–10 per cent to the transfusion of blood products (prior to 1990) and the remainder to other forms of blood-to-blood contact, such as non-sterile tattooing or other skin-incision procedures.

---

\(^5\) Barraclough Report, pp.33-34.


\(^7\) Prevalence refers to total number of people in a population who have the disease at any given time.
2.15 Since 1990, all blood has been screened for hepatitis C and the risk of transmission through the transfusion of blood or blood products in Australia is now very low. The ARCBS modelling estimates the risk of contracting post-transfusion HCV in Australia in 2000-2002 was 1 in 3,112,000.8 There is currently no vaccine against hepatitis C.

Number of people infected through blood transfusion

2.16 The Department of Health and Ageing (DoHA) stated that it is not possible to obtain comprehensive or definitive figures on the number of people infected with hepatitis C through blood transfusion. Many people with HCV are asymptomatic and may therefore never have been diagnosed.

2.17 DoHA went on to state that 'it is accepted that a history of receiving blood products before the beginning of blood-donor screening is likely to account for a substantial proportion of HCV-infected individuals who are not injecting drug users'. People with haemophilia who received fractionated plasma derivatives before heat treatment procedures were implemented were particularly at risk of being infected with HCV.9

2.18 The ARCBS provided the Committee with estimates of those living with hepatitis C gained through blood transfusions. The ARBCS estimated that between 3,500 and about 8,000 Australians live with HCV infection derived through blood transfusion, including an estimated 1,350 haemophiliacs.10 However, there is no formal reporting mechanism of post-transfusion hepatitis in Australia, as pointed out by the ARCBS:

    Australia does not operate a register where all suspected cases of post-transfusion hepatitis might be found. Some countries have established haemovigilance systems, which collect data in a central agency on all adverse outcomes (infectious and non-infectious) from transfusion, investigate and determine the cause...[I]n the early 1990s, all State and Territory governments established hepatitis C as a notifiable disease...however, these local health authorities do not necessarily record or confirm the route of transmission.11

The discovery of HCV

2.19 The transmission of blood-borne infections had been identified as an issue with transfusions since their inception. With the development of methods to monitor liver function, the term 'hepatitis' or inflammation of the liver came into use. With the use of human transmission experiments and more advanced knowledge of the disease,
‘infectious hepatitis’, which spread from person to person by the faecal–oral route, and ‘serum hepatitis’, which was transmissible by blood and blood products, were identified. In the 1970s infectious hepatitis became known as hepatitis A and serum hepatitis as hepatitis B. Hepatitis B was thought to cause post-transfusion hepatitis.

2.20 With the discovery of a protein called the B surface antigen (HBsAg), scientists were able to find an antibody which reacted with this particular protein. The antibody was subsequently used in developing tests to screen blood donors for HBV. In Australia, a surface antigen test was developed in 1970 in NSW and used throughout the country to screen donors. Professor Cossart noted that routine screening greatly reduced the incidence of post-transfusion jaundice globally. The ARCBS stated that, following the introduction of screening, the post-transfusion rate of hepatitis declined by around 20 per cent in the United States.12

2.21 The hepatitis A virus was identified in the faeces of a person with ‘infectious hepatitis’ in the early 1970s and HAV antibodies characterised in 1973. A test for antibodies (anti-HAV) then became available to study cases of post-transfusion hepatitis that were negative for HBsAg.

2.22 However, while the incidence of post-transfusion hepatitis was reduced, screening for both HAV and HBV failed to abolish the problem. People were identified with sub-clinical post-transfusion hepatitis. This had a different clinical picture from hepatitis A or B. In 1975 the name 'non-A, non-B hepatitis' (NANBH) was coined. This term was used rather than hepatitis C because at the time it was thought that more than one infectious agent was involved.13

2.23 In 1978, NANBH was successfully transmitted to chimpanzees. However, many different groups failed to find a specific virus or a laboratory marker of infection despite much intensive study. It was not until 1988 that a group of scientists at the Chiron Corporation in the United States announced the identification of the virus responsible for NANBH. A lay report appeared in *Nature* and the scientific findings were published the next year.14 This was the first virus identified by the novel approach of gene cloning, and the researchers named it ‘hepatitis C’.

2.24 Retesting of stored samples from past studies of post-transfusion hepatitis soon showed that donors with antibody to the new agent had often been implicated in transmission of non-A, non-B hepatitis. It is clear that HCV has been the cause of

---

12 Submissions 54, Appendix 3, p.A6 (DoHA); 64, p.21 (ARCBS). It should be noted that the Department of Health and Ageing commissioned Professor Cossart to address Terms of Reference (a), (b) and (f) due to their technical nature. These are at Appendices 2, 3 and 4 of the Department's submission.

13 Submission 64, p.22 (ARCBS); see also Submission 54, A9 (DoHA).

14 Barraclough Report, p.36.
liver disease for many decades (it has subsequently been found in stored blood from 1948). It was therefore a newly recognised cause of disease rather than a new virus.15

**Hepatitis C in the blood supply**

2.25 As stated above, it was noted in the 1970s that there was another agent or agents that resulted in post-transfusion hepatitis. With the introduction of testing for HAV and HBV, infection rates dropped but some recipients still acquired hepatitis. In 1978 it was observed that, since the introduction of HBV screening in the United States for donor blood, more than 93 per cent of cases of post-transfusion hepatitis were attributable to NANBH.16

2.26 Several large scale studies were undertaken to ascertain the likelihood of acquiring NANBH from blood transfusions under a defined set of circumstances. Professor Cossart noted that there were wide discrepancies in studies of post-transfusion NANBH in different countries. An Australian study of cardiac surgery patients in 1982 returned one of the lowest rates while high rates were observed in the United States, parts of Europe and Japan.17

2.27 In the United States there were great variations between blood collection centres and studies in the early 1980s attributed this to the use of blood derived from paid donors. Centres which used only volunteer blood had a much lower rate of post-transfusion hepatitis than did those that relied partially or fully on paid donors.18

2.28 The ARCBS also described two studies which were designed to define the incidence of post-transfusion hepatitis in the United States and evaluate what factors influenced its occurrence. The first, a multi-centre study published by the Transfusion Transmitted Viruses (TTV) Study Group in 1981, showed an association between NANBH and a heightened level of Alanine Aminotransferase, or ALT, an enzyme specific to liver cells produced in response to hepatitis. An independent study at the National Institutes of Health (NIH), also in 1981, confirmed the findings. In a further series of studies there was an association between NANBH and the presence of HBV core antibodies or 'anti-core', indicating prior HBV infection. This issue was extensively reviewed in the Krever Report. The ARCBS stated that there were predictions made, in the United States, that removing donors with higher levels of ALT and positive for anti-core might reduce the development of NANBH, by about a third, in recipients.19 Studies relating to surrogate testing are further discussed later in the chapter.

15 Barraclough Report, p.36.
16 Submission 64, p.23 (ARCBS).
17 Submission 54, Appendix 3, p.A7 (DoHA).
18 Barraclough Report, p.37; Submission 64, p.37 (ARCBS).
19 Submission 64, p.23 (ARCBS).
2.29 It was also known that there was a greater risk of transmission of NANBH to haemophiliac patients because the risk of infection was compounded by the use of pooled donations for the production of fractionated products. Witnesses noted that, as a result, hepatitis was common in patients with haemophilia.\(^{20}\) (The use of fractionated products by haemophiliacs is discussed later in this chapter.) However, it was generally considered that risk was acceptable because there were such significant benefits in using Factor VIII and Factor IX concentrates for the management of haemophilia.\(^{21}\)

2.30 Following the Second World War, there was awareness in Australia, and around the world, of the risk of hepatitis following transfusion. The ARCBS stated that from the early 1970s the blood transfusion service consistently warned doctors and hospitals of the risk.\(^{22}\) Studies into the transmission of NANBH were undertaken by Professor Cossart in the early 1980s and by Ismay in the 1990s.\(^{23}\) Scientific meetings were also held in Australia which addressed NANBH.\(^{24}\)

2.31 In the 1970s NANBH was considered to be a relatively minor disease with the majority of patients being asymptomatic and without any sign of severe impairment of liver function.

**Background to blood and blood products**

2.32 Blood is a major body tissue comprising plasma, a yellow, protein-rich fluid that suspends formed elements: blood cells, white blood cells and platelets. Plasma accounts for more than half of the total volume of blood. It is around 90 per cent water and contains a very complex and not fully understood mixture of proteins that perform many bodily functions.

2.33 Organised blood transfusions first emerged in the 1920s, and only whole blood was used. Over time, fractionation processes developed to the point where, today, whole blood is rarely transfused. Fresh blood products are perishable, with a shelf life of between 5 days (platelets) and 35-42 days (red cells). Red cells are the most widely used blood product.

---

20 *Submissions* 71, p.1 (ANZSBT); 82, p.8 (HFA).
21 *Submission* 82, p.8 (HFA).
22 *Submission* 64, p.24 (ARCBS).
23 *Submission* 64, p.25 (ARCBS).
24 *Submission* 71, p.1 (ANZSBT).
Table 2.2: Major fresh blood components

<table>
<thead>
<tr>
<th>Product</th>
<th>Main Uses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Red cells</td>
<td>Replacement of blood loss in trauma and surgery, and occasional treatment of anaemia.</td>
</tr>
<tr>
<td>Platelets</td>
<td>Control of bleeding related to platelet deficiencies caused by disease (eg leukaemia) or following severe haemorrhage or as a result of treatment of an underlying malignant disorder</td>
</tr>
<tr>
<td>Cryoprecipitate</td>
<td>Treatment of clotting factor and fibrinogen deficiency</td>
</tr>
<tr>
<td>White cells</td>
<td>Treatment of sepsis, regeneration of blood cells after chemotherapy.</td>
</tr>
</tbody>
</table>


2.34 Plasma products have a shelf life of between one and three years, and can be divided into three main proteins; Albumin, Immunoglobulins, and clotting factors.

Table 2.3: Principal plasma products

<table>
<thead>
<tr>
<th>Product</th>
<th>Main uses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albumin</td>
<td>Treatment of shock, burns, liver disease and kidney disease.</td>
</tr>
<tr>
<td>Immunoglobulin for intramuscular injection</td>
<td>Temporary protection from infectious diseases such as measles, rubella, and HAV.</td>
</tr>
<tr>
<td>Immunoglobulin for intravenous injection</td>
<td>Replacement therapy for primary immune deficiency disorders, such as Guillain-Barre, and Kawasaki disease.</td>
</tr>
<tr>
<td>Immunoglobulin preparations with high levels of specific antibody (hyperimmunes)</td>
<td>Treatment of tetanus or prevention of HBV, chicken pox, haemolytic disease, the newborn or cytomegalovirus.</td>
</tr>
<tr>
<td>Factor VIII concentrate</td>
<td>Haemophilia A.</td>
</tr>
<tr>
<td>Other clotting factors</td>
<td>Other bleeding disorders such as Haemophilia B.</td>
</tr>
</tbody>
</table>


Blood plasma and safety

2.35 The Barraclough Report provides an overview of issues concerning blood plasma and safety. There are two types of plasma. Recovered plasma is obtained as a by-product of whole blood collection and source plasma is obtained by collecting whole blood from a donor, separating the plasma and returning the cellular material to
the donor. The standards under which recovered plasma is collected are different from those that apply to the collection of source plasma. In particular, the safety issues are influenced by the fact that recovered plasma has to be subject to the same standards as plasma intended for direct transfusion. Source plasma is subject to safety standards that are ultimately related to the safety of the derivatives for which it serves as a raw material.

2.36 The principles underlying current concepts of the safety of blood-derived therapeutics from infection by disease producing organisms, or pathogens, are:

- the selection of donors from populations at low risk of carrying transfusion-transmitted pathogens;
- the screening of such donors using appropriate laboratory tests; and
- the treatment of the products using measures that eliminate any residual pathogens.

Although desirable, it may not be possible to have all of these principles in place concurrently.

2.37 Safety profiles differ for the two broad categories of blood-derived therapeutics – plasma derivatives and blood components. Plasma derivatives are produced from large donor pools. There is thus a greater likelihood of contamination by blood-borne pathogens than for single donor products. However, plasma derivatives are produced by industrial-scale manufacture and subject to intensive processing and quality control. In the production process, steps to eliminate pathogens can be instituted.

2.38 Viruses are the most important contaminants of plasma pools for fractionation. The amount of viral contamination in a plasma pool depends on several factors, and can be minimised through careful donor selection and laboratory screening tests. Laboratory testing measures viral genomic material, as well as the evidence of infection through, for example, antibody tests. Thus the viral load for the important blood-borne pathogens such as HBV and HCV can be reduced to very low levels.

2.39 Since the mid-1980s manufacturers have used various elimination steps that eradicate the important viruses in plasma pools. Because of the large pool size from which these products are derived, the mainstay of their safety from viral infection is the ability of the manufacturing process to eliminate viruses through deliberate steps and/or the biological features of the product.

2.40 Blood components, as opposed to plasma derivatives, are usually derived 'under conditions in which it is not possible to eliminate pathogens'. 25 For these products, the main safety techniques are donor selection and laboratory screening. The

---

25 Barraclough Report, p.32.
number of patients exposed to each product is much smaller than for plasma derivatives, which assists their safety profile.

2.41 The Barraclough Report concluded that while the safety differential between plasma derivatives and components has changed over the past twenty years, the advent of viral elimination techniques have given plasma derivatives, previously a higher-risk class of products than components, a superior safety profile. This has been achieved with the identification of agents known to cause disease, with the development of tests to identify these agents and with the refinement of existing tests to enhance sensitivity.\textsuperscript{26}

**Surrogate testing**

2.42 Surrogate testing, in the context of blood safety, refers to tests used to detect viruses for which no specific test exists and to supplement specific tests that are insufficiently sensitive.\textsuperscript{27}

2.43 During the 1980s two surrogate tests for NANBH were proposed: testing for abnormality of liver function through measurements of the level of alanine aminotransferase (ALT); and testing for markers of previous hepatitis B infection, the test for which was called anti-HBc. Professor Cossart noted that the first test assumed that donors who were infective would have abnormal liver function tests, while the second assumed that past exposure to one blood-borne virus might predict a high probability of exposure to others.\textsuperscript{28}

2.44 Witnesses reported to the Committee that before a specific test for HCV was developed there was much debate as to the usefulness of surrogate testing.\textsuperscript{29} The Royal College of Pathologists of Australia stated for example, that the decisions around surrogate testing were difficult and controversial as it is neither sensitive or specific.\textsuperscript{30} The Australian Centre for Hepatitis Virology (ACHV) concluded that:

Consequently, any decisions made to introduce (or not) surrogate screening tests were often based on interpretation of what information was available, by individuals (blood bankers) who had the unenviable task of trying to screen the blood supply for an unknown agent with no tools.\textsuperscript{31}

\textsuperscript{26} Barraclough Report, pp.32-33.
\textsuperscript{27} Krever Commission, Volume 2, p. 628.
\textsuperscript{28} Submission 54, Appendix 3, p.A10 (DoHA).
\textsuperscript{29} See, for example, Committee Hansard 5.4.04 p.36 (Dr Baird); Submission 74, p.1-2 (Professor McCaughan); 86, p.3 (Prof W Cooksley).
\textsuperscript{30} Submission 69, p.1 (RCPA).
\textsuperscript{31} Submission 80, p.2 (ACHV).
Arguments for surrogate testing

2.45 A number of witnesses submitted that surrogate testing should reasonably have been introduced across Australia from around 1986. It was argued that this form of testing represented a useful indicator of HCV status, and that its introduction would have prevented at least some infections through transfusion. It was also noted that surrogate testing was introduced in some other countries, and in Queensland in 1987.

2.46 Those supporting the introduction of surrogate testing pointed to studies conducted in the United States which were reported in 1981. The Transfusion Transmitted Viruses Study reported an association between elevated ALT in donors and the development of NANBH in blood recipients. The study predicted that by excluding donors with elevated ALT, 40 per cent of NANBH might be prevented at a loss of 3 per cent of the donor population. This low degree of supply loss was another advantage of using ALT as opposed to anti-HBc. The investigators concluded that a 'compelling argument' existed for ALT screening and exclusion to take place. In his submission to the Inquiry, Professor James Mosley, the Project Coordinator of the TTV Study, recalled reporting his findings at a conference in Brisbane in 1978. Professor Mosley reported that a number of blood bankers, including at least one senior Australian Red Cross employee, were in attendance.

2.47 A study by the National Institutes of Health in 1981 found an almost identical outcome predicting donor exclusion based on elevated ALT might prevent 29 per cent of transfusion associated hepatitis at the loss of approximately 1.5 per cent of the donor population. However, this study also noted the high incidence of false negative and false positive results, and did not recommend the introduction of ALT testing. It was stated that:

The ALT testing of donors is thus a tenuous balance between risk and benefit. The balance shifts toward testing when one considers that approximately 30 per cent of [post-transfusion hepatitis] might be prevented...but this is tempered by the realization that 70 per cent will not be prevented and that the prevention of 30 per cent is in some doubt unless confirmed by a randomized clinical trial. The balance also shifts away from testing when one considers the estimated additional $20 million in the annual cost of blood to the United States alone and the potential national loss of 45,000 donors and more than 90,000 units of blood. It is a difficult equation, whose solution will require thought and planning.

2.48 However, the NIH findings in relation to anti-HBc differed to those for ALT. The NIH report concluded:

32 See for example, Committee Hansard 5.4.04, p.26; Submission 79, p.2 (TBPAG).
33 Krever Commission, Volume 2, pp.630-32.
34 Submission 89, p.1 (Professor Mosley).
If, as predicted, surrogate screening of blood donors could prevent approximately one third of these cases, then this could represent an annual reduction of 50,000 cases of hepatitis and 2,500 cases of cirrhosis. The potential to achieve this degree of disease prevention now appears to outweigh the disadvantages inherent in the adoption of surrogate tests for the non-A, non-B virus carrier state.36

2.49 Later the TTV and NIH studies were re-analysed and an association was shown between the anti-HBc marker in donors and the development of NANBH in recipients.37

2.50 The Queensland Government was unable to provide the Committee with information about the decision to introduce surrogate testing. However, Dr Catherine Hyland, of the Blood Transfusion Service in Brisbane, published a study in 1988 which concluded, *inter alia*:

> The recent judgement in a legal suit that concerned the Queensland Red Cross Blood Transfusion Service has indicated that, provided the transfusion service is implementing screening procedures appropriate to published professional knowledge at the time of transfusion, there should not be a case for negligence at law...[I]n the light of this experience, and given the development of an assay that is cheap and convenient, it was decided that concern regarding chronic effects of NANB hepatitis outweighed the arguments against implementation of surrogate testing.38

2.51 The Haemophilia Foundation Australia (HFA) commented that, 'it appears that issues such as test sensitivity and specificity, cost and fears about reduced blood supply were considered more important than the seriousness of hepatitis'. The HFA went on to argue that 'if any kind of testing was available that could have potentially saved people from a life threatening virus, efforts should have been taken to implement these. Decisions based on cost effectiveness do not stand the test of time'.39

**Arguments against surrogate testing**

2.52 A number of arguments were put to the Committee as to why surrogate testing was not supported. First, it was argued that surrogate tests are no substitute for specific tests such as antibody tests. Because of the lack of sensitivity and specificity, it is difficult to ascertain their effectiveness in identifying the blood donations that should be excluded.40

37 Submission 64, pp.36-37 (ARCBS).
39 Submission 82, p.10; Committee Hansard 5.4.04, p.3 (HFA).
40 Submission 64, p.36 (ARCBS); see also Submission 69, p.1 (RCPA).
In relation to the two surrogate tests proposed for NANBH it was pointed out that there were problems with both tests. For ALT, it was argued that, by its nature, it was not specific to NANBH. There were a number of reasons why ALT levels may be raised, including individual lifestyle factors such as exercise, alcohol, use of many common medications and simple obesity.\(^{41}\) The Barraclough Report noted that:

ALT measures a normal liver enzyme. This is not a measure of the presence of a particular hepatitis virus. Rather, elevated ALT levels may be a sign of liver inflammation, commonly caused by hepatitis. However, as ALT levels are affected by many drugs, including even modest amounts of alcohol, many units of non-infective blood gave abnormal results. Furthermore, at least some infective units had normal values. In addition, an ALT elevation may not mean the person has any medical abnormality.\(^{42}\)

As a result there would be high levels of donors rejected unnecessarily.

There was also considerable debate at the time about the significance of raised ALT levels and the ALT cut off level where blood should be discarded. For example, it was known that ALT levels could vary even where the individual was a carrier of the NANBH agent. The person could thus have an ALT level above the cut off on one day and a lower ALT level on another day.\(^{43}\) Professor Geoff McCaughan, in his submission to the Committee, pointed to a number of reviews published in the mid 1980s which addressed the inadequacies of surrogate testing.\(^{44}\)

Professor Cossart referred to a review of the issue of surrogate testing over the past three decades published in 2000 that concluded that 'despite its conceptual appeal, ALT screening had never been substantiated as a routine measure to prevent post-transfusion NANB hepatitis, and its introduction was driven by concern about the emerging problems in recipients rather than evidence of its efficacy'.\(^{45}\)

In evidence from CSL, Dr Darryl Maher provided the Committee with a graph generated by the Therapeutic Goods Administration. The graph, reproduced as Figure 2.1, plots the course of viral load in an individual over the days following infection. Dr Maher's explanation of the graph and its consequences for ALT testing is worth quoting at length:

This is from time zero, the point at which the individual is infected, and this is the course of the infection in days, out to 100 days. The Y axis is the level of virus in the blood. That axis is actually on a logarithmic scale, which means that at each point going up the Y axis we are talking about tenfold more viruses. At this point down here there may be, say, 100 viruses

\(^{41}\) Submissions 64, p.36 (ARCBS); 86, p.2 (Prof W Cooksley).

\(^{42}\) Barraclough Report, p.39.

\(^{43}\) Submission 64, p.39 (ARCBS).

\(^{44}\) Submission 74, p.3-6 (Prof McCaughan).

\(^{45}\) Submission 54, p A15 (DoHA).
per millilitre; up here, it would be of the order of 10 million viruses per millilitre – so many, many thousandfold more. After infection, within about a 10- or 11-day period, the virus starts to appear in the bloodstream in the individual – and this is it going up here. The tests that can detect that are the NAT tests, which you have heard about, because they are measuring the virus itself.

With regard to the earlier tests, let us start with the surrogate testing, the ALT marker. That is a marker of inflammation in the liver, so it only goes up once the infection has taken hold and the liver has become inflamed. You can see the ALT peak on this graph here which shows that it is some 50-odd days after the infection before the ALT starts to go up. So for donors who may have been infected and are at risk of transmitting you have this 55-day period with extremely high titres of virus, and none of these tests—the ALT or, for that matter, the antibody tests – are able to detect it.

The unfortunate irony, in a way, is that the time when the antibody takes off and the ALT is coming up is the time when the level of virus actually starts to fall. So the level of virus in the group that are positive for ALT is about 10,000-fold less than the level of virus in this group of individuals who are in the incubation period before their test becomes abnormal. We are talking about 10,000 to one, so if you have got a 10,000-donor pool you only need to have one person in this period for there to be as many viruses as having all 10,000 of them with a positive ALT test.

That is how dramatic the difference is in the level of virus during that course. This information is in retrospect and it was not available to the committee making decision at the time. I think other reasons drove the decision back then. What I am saying is that, in retrospect, it is very clear that ALT testing would not have reduced the risk of transmission by these concentrates.46

---

46 Committee Hansard 5.4.04, pp.47-48 (Dr Maher).
2.57 In relation to anti-core testing, Professor Cooksley noted that it had the advantage of being positive or negative rather than being a continuous variable. However, the disadvantage was the high rate of false positive and false negative results. Anybody with a past exposure to HBV would be automatically excluded. Thus people from the Mediterranean countries, Eastern Europe, the Middle East, Asia, Pacific region, Africa and South America would have a high likelihood of being excluded as HBV is common in those regions. However, only about half of the HCV-positive donors would be excluded, since the test relies on previous exposure to HBV.\textsuperscript{47}

2.58 The need for surrogate testing was also questioned as the studies supporting the introduction of testing were derived from the United States, where the epidemiological context differed significantly from that of Australia.\textsuperscript{48} This raised the question as to whether it was appropriate or necessary to introduce surrogate screening in Australia. The Barraclough Report stated:

The greatest potential benefit from using surrogate tests was in countries where the risk of transfusion transmitted hepatitis was highest, notably in countries that used blood and blood products from paid donors.\textsuperscript{49}

2.59 Professor McCaughan also pointed out that not only did Australia have a volunteer donor system but also a successful HIV screening questionnaire programme

\textsuperscript{47} Submission 86, p.2 (Prof W Cooksley).

\textsuperscript{48} See, for example, Submission 74, p.1 (Prof McCaughan).

\textsuperscript{49} Barraclough Report, p. 40. See also Committee Hansard 6.4.04, p.62 (Prof Barraclough).
had been introduced in Australia while in the United States neither precaution was taken.\textsuperscript{50} The Barraclough Report also commented on the significance of HIV questionnaires and found that:

The majority of data supporting the efficacy of surrogate testing were obtained before the introduction of donor screening by questionnaire and serological testing for HIV. Both of these activities were likely to have significantly reduced the effectiveness of the surrogate screening protocol by excluding a significant proportion of the same risk group.\textsuperscript{51}

2.60 The ARCBS submitted that 'Australian blood bankers took all questions of safety extremely seriously and thoroughly reviewed and considered the "surrogate marker debate" as it evolved in the United States, Europe and the United Kingdom'. However, it was decided, through the National Blood Transfusion Committee, not to recommend the introduction of surrogate testing 'following an evaluation of the scientific evidence for surrogate testing because the evidence that it would be effective was not convincing'. Surrogate tests were considered to be 'blunt and inaccurate tools with the potential to create blood shortages without any demonstrated benefit to public safety'. Further, surrogate tests had not been proven to be effective in reducing post-transfusion hepatitis.\textsuperscript{52}

2.61 In relation to the introduction of surrogate testing in Queensland, the ARCBS stated 'the fact that the BTS in Queensland, having reviewed the same international data and arguments as the other services, reached a different conclusion from the remaining states is evidence of the highly controversial and inconclusive nature of the "surrogate marker debate"'.\textsuperscript{53}

\textit{Surrogate testing internationally}

2.62 The inconsistent approach taken internationally was borne out by evidence on the introduction of surrogate testing overseas which was provided to the Committee. For example, in the United States in 1983 a report from the American Association of Blood Banks concluded:

\begin{quote}
While we share the desire of the entire medical community to reduce the incidence of transfusion associated hepatitis, we believe that currently available evidence does not justify either universal testing of donor blood for ALT or the rejection of donors who have elevated levels. Therefore, at this time we do not advise routine donor testing for ALT as a means of reducing the incidence of non-A, non-B hepatitis.\textsuperscript{54}
\end{quote}

\begin{itemize}
\item \textsuperscript{50} Submission 74, p.1 (Prof McCaughan).
\item \textsuperscript{51} Barraclough Report, p.41.
\item \textsuperscript{52} Submission 64, p.39; Submission prepared for hearing 7.4.04, p.12 (ARCBS).
\item \textsuperscript{53} Submission 64, p.42 (ARCBS).
\item \textsuperscript{54} Krever Commission, Volume 2, p.635.
\end{itemize}
2.63 However, the US Blood Banks adopted surrogate testing at various times up to mid 1987. The US Food and Drug Administration blood products advisory committee found that surrogate testing should be implemented. Despite the recommendation of its own blood products advisory committee, and introduction of surrogate testing by Blood Banks, the FDA did not issue a regulation requiring anti-HBc testing of donated blood until 1 March 1991, and then for the purpose of identifying units contaminated with HBV, not HCV. The FDA never issued a regulation requiring testing for ALT levels, and only a 'handful' of US blood centres implemented it as a matter of course. However, the American Association of Blood Banks recommended in 1986 that testing be introduced and this occurred in 1986-87.55

2.64 Few other countries introduced surrogate testing in the mid 1980s. The United Kingdom did not implement surrogate tests. The average rate of post-transfusion hepatitis was believed to be less than one per cent, so low that British blood bankers questioned whether it was cost effective to implement even anti-HCV testing, when it became available.56 No European countries performed anti-core testing and only parts of Germany and Italy conducted ALT testing. The ARCBS noted that Germany had introduced ALT testing in the 1970s but it still had a very high rate of post-transfusion hepatitis.57

2.65 In May 1987, the Council of Europe's Committee of Experts on Blood Transfusion and Immunohaematology concluded that:

Arguments against the introduction of surrogate testing include the variability of data from one country to another, the non-specific nature of the tests proposed, loss of apparently healthy donors, difficulty in follow up of the donors and the continuation of transfusion-transmitted NANBH in spite of the tests.58

2.66 Those in support of surrogate testing argued that the prospect of a reduction in the supply of blood (owing to the need to discard blood which may nor may not have contained HCV) was a major factor in the decision not to introduce surrogate testing.

2.67 The ARCBS stated that the level of donations was a 'major concern' as it was estimated that at least five per cent of voluntary blood donations would be rejected even though they were mostly expected not to be infectious. The false positive result from the ALT test might occur if the donor was overweight, or used alcohol heavily before donating, or was taking certain medicines. The ARCBS also noted that it was during this time that there was concern about the adequacy of the blood supply as the AIDS epidemic had led to a fall in collections.

55 See, for example, Submission 82, p.9 (HFA).
56 Barraclough Report, p.41.
57 Submission 64, Submission prepared for hearing 7.4.04, p.12 (ARCBS).
58 Submission 64, p.39; Submission prepared for hearing 7.4.04, p.12 (ARCBS).
2.68 In addition, the Blood Transfusion Services were mindful of causing needless alarm in donors by advising them that they may have contracted hepatitis. Many donors would have been referred to medical practitioners for investigation and possibly even a liver biopsy, a procedure with risks of its own, even though the great majority of donors would be healthy.

2.69 The ARCBS also argued that such a move might also have been counterproductive, as lost donors would need to be replaced and a consequent increase in new donors would have brought an increased risk. New donors were known from experience with HIV and HBV to have much higher rates of infectious disease markers than repeat donors were.59

2.70 In Queensland, during the three year period of ALT testing over 4,400 donations were estimated to have been discarded. Many new donors were required and the ARCBS stated that this created problems for the Queensland BTS. It added that, in retrospect, it was clear that 92 per cent of the blood Queensland rejected was in fact good blood. The ARCBS concluded that 'essentially surrogate testing was casting a very wide net in which you may have caught just a few of the infectious donors but also a lot of good safe donors got caught as well'.60

2.71 It was also suggested in evidence that the costs associated with surrogate testing bore an impact on decisions as to its use.61 The Tainted Blood Product Action Group (TBPAG) claimed that the ARCBS had:

[a] desire to place commercial considerations before the primary responsibility of maintaining a safe blood supply…62

2.72 The Committee received evidence from the ARCBS addressing the cost of surrogate testing as follows:

We have examined records from the relevant time held by ARCBS nationally and found only one specific estimate. That was from NSW, the largest Blood Service. NSW estimated that the cost of conducting ALT tests alone for the year 1987-1988 would have been approximately $250,000. This figure did not include any costs associated with replacing lost donors. Based on NSW representing about 33% of Australia's blood collection at the time, one could therefore project the total Australian costs for ALT testing might have been in the order of $750,000 - $800,000 per annum.63

59 Submission 64, Submission prepared for hearing 7.4.04, p.13 (ARCBS); see also Committee Hansard 5.4.04, p.51 (CSL).
60 Submission 64, Submission prepared for hearing 7.4.04, p.14 (ARCBS).
61 Submission 82, p.10 (HFA).
62 Submission 79, p.2. (TBPAG)
63 Submission 64, Response to Questions, 18.5.04, p.2 (ARCBS).
With respect to anti-core testing, the ARCBS went on to provide the following:

The core antibody test was estimated by Queensland to cost more than ALT testing. In June 1992, it was referred to as having been costed in 1987 at $250,000 per annum for Queensland. Based on Queensland representing approximately 17% of Australian collections in the late 1980s this would equate to a cost of about $1.47 million nationally per annum.\footnote{Submission 64, Response to Questions, 18.5.04, p.2 (ARCBS). The ARCBS emphasised that these figures were estimates only.}

2.73 The ARCBS strongly rejected the claims concerning costs, arguing that cost issues were never a consideration by the (then) Australian Red Cross in their assessment of the usefulness of surrogate testing in the Australian context:

Commercial considerations played no part in the decision making. It is important to note that cost was not a consideration and has never been claimed to be an issue in the decision making on this surrogate testing in Australia. Red Cross funding at that time was not reliant on the volume of collections therefore any fall in collections did not affect funding.\footnote{Submission 64, Submission prepared for hearing 7.4.04, p.13 (ARCBS).}

2.74 Appearing in Sydney, Professor Barraclough summarised what he considered to be an extremely difficult decision making process:

My view is that the issues were considered effectively by quite serious and concerned people who were trying to balance quite momentous national issues in effect but without adequate scientific knowledge to give them the certainty and security that they would normally have when taking decisions of this nature…[T]he fact that Australia was so early in introducing the first [antibody] test says that people were taking those issues of public safety very seriously.\footnote{Committee Hansard 6.4.04, p.65 (Professor Barraclough).}

2.75 Professor Burrell of ACHV concluded:

In looking back now to assess what might or might not have been instituted at a certain point in time, two further considerations apply. (i) Armed with our current knowledge about HCV, it is hard to fully appreciate the uncertainty and lack of quantitative information available before 1989, and also in the period 1989-1992. Furthermore, the number of false starts and blind alleys that occurred during the 1980’s had created a certain sense of caution against immediately adopting possible new measures. (ii) There have been changes in society’s tolerance of risk from blood transfusion. Prior to the 1980’s, the measurable risk of hepatitis from blood transfusion was acknowledged and enormous efforts were made to reduce this to a lower level, compatible with the requirement to maintain blood supplies. The success of these efforts, the reduction in the risk of transfusion-transmitted HIV, and the institution of nucleic acid screening to even further reduce the transmission of specified agents, have all contributed to a
current climate where, in balancing cost-benefit issues of blood safety versus possible blood shortage, a particularly high expectation is now required for safety from transfusion-transmission of hepatitis.\textsuperscript{67}

2.76 Dr Baird expressed a general view of the majority of medical witnesses, putting it this way:

\ldots\textnormal{[I]}nternationally there was some wide disparity over what was and what was not appropriate. Some countries were performing testing; others were not. It was purely on the evidence that some people evaluated different evidence in different ways; it was not a universal approach internationally. In retrospect it is easy to look back and say, 'Ah, how progressive' but on the other hand it was not retrospect at the time.\textsuperscript{68}

2.77 The Royal College of Pathologists of Australia stated that surrogate testing may have decreased, though not eliminated, the transmission of NANBH but 'this does not mean that the introduction of such testing was appropriate'. The RCPA commented that factors in the decision would be:

\begin{itemize}
\item the predicted decrease in the transmission of hepatitis by the introduction of surrogate testing;
\item the percentage of donors deferred on the basis of surrogate testing and the impact that this would have on the adequacy of the blood supply
\item the impact on the deferred donors themselves, especially as many would not actually have significant illness.\textsuperscript{69}
\end{itemize}

The possible prevention of hepatitis C infections by earlier implementation of surrogate testing and donor deferral

2.78 Submissions from the ARCBS and the paper prepared by Professor Cossart for the DoHA addressed the issue of the number of infections which may have been prevented had surrogate testing and donor deferral been implemented earlier.

2.79 The ARCBS stated that 'it is almost impossible, hypothetically, to quantify the potential benefit of surrogate testing or the impact on the blood supply of its introduction in Australia'. Rather the ARCBS provided evidence on the countries that did introduce surrogate testing and their retrospective view of the benefit.

2.80 In the United States various studies found that:

\begin{itemize}
\item 91 per cent of US donors with elevated ALT and 95 per cent with anti-core were HCV negative;
\end{itemize}

\textsuperscript{67} Submission 80, p.3 (ACHV).

\textsuperscript{68} Committee Hansard 5.4.04, p.36 (Dr Baird).

\textsuperscript{69} Submission 69, p.1 (RCPA).
• the introduction of surrogate testing in 1986-1990 resulted in little difference in the proportion of multi-transfused patients who developed HCV;

• the most significant drop in the incidence of NANBH occurred with the exclusion of paid donors and the introduction of the HBV surface antigen test in 1970; and

• the combined effect of ALT testing and implementation of anticore as a surrogate test in 1987 was a drop in the incidence of NANBH from 5.5 per cent in 1981 to 4.1 per cent. This change in 'background risk' was significant.70

2.81 The ARCBS noted that reductions in post-transfusion NANBH occurred in countries without the introduction of surrogate testing. For example, the rate in Canada declined from 9.2 per cent the early eighties to 3.2 per cent in the late eighties. Other studies from Australia and Europe showed similar results. It was believed that reductions in the risk of NANBH were due to the introduction of other preventative measures. The major measures were the limiting of the amount of blood given to an individual; phasing out of paid donors; and more intense screening of volunteer donors.71

2.82 Professor Cossart stated that some anti-HCV positive donations would have been rejected and a proportion of post-transfusion NANBH cases prevented had surrogate testing and donor deferral been implemented during the 1980s. The number of cases prevented and overall effect would have depended on the actual level of the cut off level used to define ALT abnormality; the ethnic and social composition of the donor panel of the time, and the actual rate of post-transfusion NANB hepatitis following transfusion of units retained or rejected.

2.83 Professor Cossart noted that it is not easy to make an assessment in retrospect and even at the time as surrogate testing was only one of four major strategies used during the 1980s to reduce the risk of NANBH after blood transfusion. In addition, few large scale trials on the effect of each measure were undertaken.

2.84 Professor Cossart estimated the hypothetical benefit in Australia from exclusion of donors using surrogate markers:

If surrogate testing for both raised ALT (>50IU/L) and anti-HBc alone had been introduced during the late 1980s approximately 512 (0.091%) units would have transmitted HCV each year compared with 615 (0.11%) had the same number of donors been deferred on the basis of an arbitrary marker such as the initial of their surname.

The number of cases of hepatitis C prevented would have been substantially less as most patients receive multiple units of blood. Factors which would have attenuated the

70 Submission 64, pp.43-9 (ARCBS).

71 See also Committee Hansard 1.4.04, p.2 (ACHV).
impact are that the risk of persistent post-transfusion HCV is less than 25 per cent of the risk of transmission and the risk of chronic HCV related liver disease is still lower.\textsuperscript{72}

**First generation test for hepatitis C**

2.85 The molecular characterisation of the hepatitis C virus in 1989 led to the rapid development of a test for antibody to the virus. Epidemiological studies quickly revealed that HCV was the cause for at least 80–90 per cent of NANBH. The first generation antibody test was subsequently shown to be capable of preventing the transmission of 75 per cent of transfusion-transmitted HCV, the major source of non-A, non-B hepatitis.\textsuperscript{73}

2.86 The first tests designed to measure anti-HCV antibodies became available commercially in late 1989. The first HCV kits measured antibody to the C-100 antigen, which is not part of the infectious HCV particle itself, but is made in infected cells as the virus grows. Antibody against the C-100 antigen appears irregularly in acute infection but is usually present in chronic carriers of HCV. Antibodies of this type do not protect against infection, and may cross-react with antigens induced by other related viruses. Professor Burrell stated:

The first screening test used a very small area of the antigens of the virus and the technology was not as good at dealing with cross-reactions or non-specific binding patients antibody. So some patients in whom the antibodies that had developed did not happen to match up with the narrow range of antigens in the test would have had true antibody but it would not have come up in the test, and that would have given a false negative result. Then there would be other patients in whom the screening test would give a positive reaction. The reason would not be that they had the hep C antibody; the reason would be that they had some other kind of reactivity, that the plasma was sticky or some other unrelated reason.\textsuperscript{74}

2.87 The Barraclough Report noted that for many months after the introduction of the tests, there was no independent means of confirming a positive result and this placed transfusion services worldwide in a difficult position. Initial screening of donors revealed a higher rate of positive test results than would be anticipated given the rate of clinical post-transfusion hepatitis. For example, the ARCBS stated that, 'in the first phase, 70 per cent of the people who reacted on the test were false positive; so they did not have HCV at all'.\textsuperscript{75} There was also very little knowledge about the significance of a positive test result in terms of the risk of developing significant liver disease or of infectivity to contacts in everyday life. There was consequently no

\textsuperscript{72} Submission 54, Appendix 4, p.A22 (DoHA).
\textsuperscript{73} Barraclough Report, p.41.
\textsuperscript{74} Committee Hansard 1.4.04, p.4 (ACHV).
\textsuperscript{75} Committee Hansard 7.4.04, p.60 (ARCBS).
consensus about the most appropriate approach to counselling donors who tested positive for anti-HCV antibodies.⁷⁶

2.88 Australian blood transfusion services decided to introduce screening of donations using the first generation C-100 test in November 1989 with commencement of use of the kits by all Blood Transfusion Services in Australia by 19 February 1990. It was expected that confirmatory tests would rapidly become available given the volume of research being conducted by the Chiron group and others, particularly in Japan.

2.89 Australia was one of the first countries to use the first generation test kits, with most countries introducing the kit during 1990-91. Specifically, these included France and Finland as of May 1990, Canada in June 1990, the USA (Blood Sector) between May and November 1990, the United Kingdom by September 1991 and Denmark by early 1991.⁷⁷

2.90 While there were some reservations expressed on the accuracy of the first generation test, Professor Burrell commented:

I do not have the percentages in front of me as to what we think their performance was compared to the best standard now, but I am fairly sure that even the first generation tests would have been well in the range of 75 per cent to 95 per cent reliable compared to what we have got now, which is just an extraordinarily large improvement on anything that surrogate markers were attempting to do. The introduction of the first generation test in 1990 was an absolute watershed, moving from being in the dark blindfolded to having a fairly reliable window on what was going on.⁷⁸

2.91 This test is estimated to have prevented 75 per cent of blood-transmitted HCV in the USA, or 40,000 patients per year.

Testing and exclusion of products destined for fractionation

2.92 It is clear that there was a significant divergence of scientific opinion and debate internationally as to the use of plasma testing positive to the newly developed anti-HCV test for the manufacture of plasma products, and the relative safety of immunoglobulin produced with such plasma. Based on the incomplete scientific knowledge of the time, and after wide consultation and detailed discussion of the conflicting evidence, the decision was taken to allow plasma that tested positive to the first generation anti-HCV test to be sent to CSL. This occurred from February 1990, when anti-HCV testing was introduced, through to July 1990.⁷⁹

⁷⁶ Barraclough Report, p.41.
⁷⁷ Barraclough Report, p.42.
⁷⁸ Committee Hansard 1.4.04, p.5 (ACHV).
⁷⁹ Submission 64, Additional information, 10.5.04, p.1-4 (ARCBS).
2.93 The Expert Advisory Group chaired by Professor Barraclough found that positive plasma was allowed to be fractionated for the production of specific products, none of which had been associated with hepatitis transmission provided that particular manufacturing processes were followed. The Group also found that plasma testing positive continued to be stored with CSL until July 1991 for use in research, but that the stockpile was destroyed by May 1994.

2.94 The decision to allow plasma which tested positive to be fractionated for certain products was in accordance with the stated policy of the United States Food and Drug Administration, which considered that the immediate use of the first generation anti-HCV test to exclude plasma for further manufacture was premature.

2.95 However, further consideration by the Red Cross in April and May 1990 led to a reversal of this decision. One key consideration was the publication in *The Lancet* in May 1990 of a letter from the Director of the Scottish Red Cross Blood Service, Dr John Cash, who considered that a continuation of the FDA’s policy of inclusion of plasma which tested positive could be regarded as 'a major breach of good manufacturing process'.

**Testing and notification policy in the introductory phase**

2.96 The Barraclough report commented that in 1990, first generation antibody tests returned a large number of false positive results. Confirmatory tests for hepatitis C were not available for many screened anti-HCV positive donors, particularly in the first three quarters of 1990, and this created difficulties in identifying true positive results. This also lead to greater difficulties in counselling the donors who tested positive. As a result, the Blood Transfusion Service Executive Sub-committee decided in a meeting on 22–23 February 1990 that donors who were repeatedly reactive to anti-HCV screening would not be notified in the first instance. It was agreed at that meeting that donors who were repeat reactive to anti-HCV and had a raised (ALT) at a subsequent donation would be notified and referred to a gastroenterologist.

2.97 As an interim measure, donations testing positive in the C-100 test were retested by the same means. Units which tested positive a second time were withdrawn from routine use and sample was stored for confirmatory tests in the future. An additional test using an assay was called recombinant immunoblot assay (RIBA) was available in limited quantity during the Phase 1 period. The RIBA confirmatory testing commenced in NSW on 3 September 1990, as soon as the kits were commercially available. A small number of trial kits had been provided earlier in the year by Ortho Diagnostics for research purposes.

---

80 For further information on the decisions taken regarding fractionated products at this time, see Barraclough Report, pp.60-82.

81 The description of events occurring around 1990 in this section was largely drawn from the Barraclough Report, pp. 5-16; 43-44.
2.98 Donors whose blood repeatedly tested positive to hepatitis C screening tests continued to donate for plasma fractionation products only, until July 1990. Donors were not deferred from making donation until tests that could confirm their HCV status became available. These tests were not universally available until towards the end of 1990, although the first tests became available in September 1990.

2.99 Donor follow-up included further testing at three and six months, including an interview with a blood transfusion service medical officer, to establish if they were still infected.

2.100 The management of anti-HCV (positive) repeat reactive donors was discussed again at a BTS Executive Sub-committee meeting on 18 July 1990. At the meeting it was noted that the majority of blood transfusion services were abiding by the February decision of the BTS Executive Sub-committee. It was agreed that donors should be referred to an appropriate clinician if they were repeatedly reactive to HCV testing as well as showing raised ALT level, and were positive to a confirmation test. It was acknowledged at this meeting that confirmatory tests for HCV antibody were not always available. When confirmatory tests became available and confirmation of HCV positive status was achieved, such patients were counselled, referred to an appropriate clinician and deferred from donation. From December 1990, following discussion at the BTS Executive Sub-committee, repeatedly reactive screening tests were considered as a basis for deferral until true confirmatory tests became available.

2.101 In evidence to the Committee, one witness related his experience of blood donation, expressing concern at being encouraged to donate even after his positive hepatitis status was confirmed.82 Indeed, the Barraclough Report indicated that, depending on the State or Territory, antibody-positive plasma continued to be shipped to CSL as late as July 1991. However, the Expert Advisory Group concluded that, while donations may have been made, blood testing positive almost certainly was not used by CSL to produce plasma products.83

2.102 In a supplementary submission to the Committee, the ARCBS reported that a study was conducted during 1990 to investigate the efficacy of the first generation HCV antibody test, and that some donations made after July 1990 which tested positive to the test were used in that study. The ARCBS indicated that contributors to this study were advised that their donations may also be used for fractionation into products carrying no risk of transmission post manufacture.84 ARCBS also stated that any plasma testing positive after July 1990, not used for the study, was stockpiled at CSL with a view to its use in the production of a new hyper-immune anti-HCV immunoglobulin. This stockpile was subsequently destroyed, the project unrealised.

---

82 Committee Hansard 6.4.04, p.37.
83 Barraclough Report, p.12.
84 Submission 64, supplementary submission 10.5.04, pp.2-3. (ARCBS).
Second generation testing

2.103 With advances in the understanding of the hepatitis C virus and refinements in molecular technology, a second generation test based on a series of antigens derived from other HCV genes was developed in 1991. Professor Burrell noted that the new tests improved the range of antibodies they detected and could detect closer to 100 per cent of true infections. Approximately half of the donors who tested anti-HCV positive in the first generation test remained positive in the second.

2.104 Professor Burrell went on to state:

Early on we did not really have any other yardstick. Subsequently, what has become more and more available is a means to detect the virus rather than the antibody. The presence of the antibody usually would be a reflection that the patient had been infected. If infection invariably leads to persistence, as it does with HIV, you can take the presence of antibody as proving the patient is now infected. But, with hepatitis C, we believe that only 65 per cent to 85 per cent of people with antibody are truly infected still and the rest have their antibody but have cleared the virus.85

Testing for hepatitis C today

2.105 In testing for hepatitis C, a sample of blood is taken and tested to determine whether the person’s body is producing antibodies to the virus. After exposure to the virus it can take up to six months before antibodies can be detected. This is known as the window period.

2.106 An HCV RNA test, sometimes called PCR (polymerase chain reaction test), is now used. This tests for the presence or absence of the virus itself (the viral RNA). The test is generally used when assessing people for treatment and can also be used where an antibody test result is indeterminate. Professor Burrell stated:

There are still problems with that test because that only has a certain sensitivity and, if a patient has a fluctuating level of virus, there may be times when the level goes under the sensitivity level and then comes up again. So they may appear negative and then be positive a week later.86

2.107 As to the overall quality and accuracy of testing in 2004 by the ARCBS, Professor Elizabeth Dax, Director of the National Serology Reference Laboratory, which is charged with assuring the quality of HIV and HCV tests in Australia, stated:

Not only does the ARCBS strive to put in place the most appropriate methods but they are certainly followed rigorously, in a batch-by-batch way, on a continuous basis. I think all the tests and innovations have been

85 Committee Hansard 1.4.04, p.4 (ACHV).
86 Committee Hansard 1.4.04, p.5 (ACHV).
put in place not only promptly but in a very controlled manner and in such a way that they have been able to be checked on a continuous basis.\(^87\)

**Conclusions**

2.108 The Committee received evidence that there was widespread controversy surrounding the use of surrogate testing in respect of hepatitis C. The Committee considers that this inhibited the ability of authorities around the world in making decisions on its implementation. Australia was no exception, and a good deal of time and resources were spent in search of a definitive outcome, to little or no avail.

2.109 There is evidence to suggest that the relevant authorities in Australia could have instigated surrogate testing prior to the introduction of the antibody test in 1990. However, the Committee was presented with much compelling evidence as to why surrogate testing was not introduced.\(^88\) It seems to the Committee that, based on the information available at the time, it was open to the relevant bodies to take the decisions they did. It is in this context that the concept of equipoise arises, whereby, to quote Professor McCaughan:

> If on the balance of the evidence you do not know what to do, then either choice is ethically acceptable.\(^89\)

2.110 The difficulty associated with the decision making process at the time was also acknowledged by the Hepatitis C Council on New South Wales:

> On balance while we regret, in the strongest possible terms, that hepatitis C infections arose as a result of this decision, we do not believe that negligence or at fault activities occurred.\(^90\)

2.111 The Committee therefore considers that, at the relevant times, decisions made in relation to surrogate and antibody testing were not inappropriate. The Committee is confident that due consideration was given to pertinent evidence at relevant times, and that decisions were reasonable in the circumstances.

**Australia's self sufficiency in blood stocks**

2.112 The Department of Health and Ageing (DoHA) stated that the aim of national self-sufficiency in blood supply has been part of official Australian policy since 1975.\(^91\) The policy for self-sufficiency arose out of an international concern that some commercial fractionators were buying plasma from persons in developing countries.

---

\(^87\) Committee Hansard 5.4.04, p.29 (Professor Dax).

\(^88\) See, for example, Committee Hansard 6.4.04 p.65 (Professor Barraclough); Committee Hansard 5.4.04, p.46 (Dr Maher).

\(^89\) Committee Hansard 6.4.04, p.94 (Prof McCaughan).

\(^90\) Submission 81, Additional Information 9.6.04 p.4 (Hepatitis C Council of NSW)

\(^91\) Submission 54, p.12 (DoHA).
This posed a risk both to the paid donors and to the recipients of products made from plasma.

2.113 Australia's aims in relation to blood and blood products are set out in the recent National Blood Agreement between the Commonwealth and State/Territory Governments where one of the policy aims is 'to promote national self-sufficiency'.

2.114 The Committee heard that, in developed countries such as Australia, self-sufficiency could be taken to imply a sufficient supply of both fresh blood components and fractionated plasma products such as albumin, clotting factors and immunoglobulins. This would normally be achieved through a national blood program without the need to source products from other countries. A blood donation rate of 50 per 1000 population is the general minimum donation rate required for a developed country to meet this objective. In Australia, this translates to around 20,000 donations per week being needed to keep supplies at sufficient levels.

**Figure 2.2: Blood Donations from 1998-2003**

![Blood Donations from 1998-2003](image)

*Source: Annual Report 2002-03 Australian Red Cross Blood Service, p.13.*

2.115 Figure 2.3 shows the total number of blood collections from 1994-95 to 2002-03.

---

92 Submission 54, p.12 (DoHA).

93 Submission 64, p.62 (ARCBS).
2.116 According to the ARCBS, Australia is in the minority of developed countries which are able to stay fully self sufficient in fresh blood stocks, and almost completely self sufficient in plasma products.\(^{94}\) This is especially noteworthy as Australia's donors are all voluntary and totally un-remunerated.

2.117 The mid-1980s saw a considerable tightening of donor eligibility, due to the advent of HIV/AIDS. This inevitably led to a reduction in the donor pool, and by 1988 total collections had fallen by 16,000 over the preceding year. It should be remembered that it was around the time of this decline that the prospect of surrogate testing, and the attendant reduction in yield, was being considered in Australia. This reduction in yield was an important concern for those considering the introduction of the testing.\(^{95}\)

2.118 Tightening of donor eligibility also had an effect on the supply of plasma intended for fractionation, although the ARCBS submitted that 'by and large' the demand for plasma products was still met from within Australia.\(^{96}\) The ARCBS notes

---

94 Since 1990, various plasma products have been imported due to low demand. For a more detailed discussion, see Submission 64, p.64 (ARCBS).

95 Submission 64, p.62 (ARCBS). A state-by-state précis of the blood supply scenario in the 1980s is also available in the ARCBS Submission.

96 Submission 64, p.64 (ARCBS).
that certain specialised products, such as Factor VII and Factor XI, which were required by a small number of patients per year, were imported.97

2.119 Australia's near total self-sufficiency was lauded by the Stephen Review, which found that:

Under these [largely self-sufficient] circumstances, continuing high levels of safety and quality should be achievable, as long as careful national policy measures and strong regulatory oversight are maintained.98

2.120 Australia's goal of self sufficiency of blood stocks drew criticism from the Haemophilia Foundation, which was supportive of the increased use of recombinant therapies, manufactured overseas, to completely eradicate the risk of blood-borne virus transmission.99 This is discussed further in Chapter 6.

Blood from overseas being used in Australia

2.121 It was submitted by the TBPAG that CSL had 'mixed Australian blood with blood from several foreign countries for distribution in Australia'.100

2.122 The TBPAG refer to an Australian National Audit Office Report relating to unauthorised processing of foreign-sourced blood plasma by CSL, occurring in the mid 1990s.101 The ANAO report does not conclude that products derived from foreign-sourced plasma were used in Australia, nor does it conclude that cross-contamination between foreign and domestic plasma batches occurred.

2.123 In evidence Dr Maher advised that, prior to 1984, CSL blended Australian and New Zealand plasma for the manufacture of clotting agents where supply was insufficient from either country. Dr Maher pointed out that similar standards were applied in each country to the screening of volunteers and donation testing. Dr Maher then stated:

Apart from the New Zealand example, CSL has never imported or purchased plasma for the purpose of manufacturing products for therapeutic use in Australia.102

97 For detailed information on all blood products imported into Australia, see Senate, Hansard, Question No.1781, 18.9.03, pp.15652-3.

98 Stephen Review, p.xi.

99 Committee Hansard 5.4.04, p.7 (HFA).

100 Submission 74, p.19 (TBPAG).


102 Committee Hansard 5.4.04, p.45 (Dr Maher).
Collection from prison inmates

2.124 The TBPAG raised the Australian Red Cross state divisions' collection of blood from prison inmates.103 The Committee understands from information provided to the Senate that this practice had ceased by the following approximate dates: New South Wales, mid 1970s; South Australia, 1975; Western Australia, early 1980s; Victoria, 1983; and Tasmania, 1983.104

The global plasma market

2.125 Australia's experience of blood donation stands in contrast to many other developed nations. In the United States, blood and plasma has for many years been imported from Europe to supplement the supply required to service major centres like New York. While paid donation has now been phased out for fresh blood products, it was a feature of the American blood supply for many years, and remains an important element in harvesting plasma.105

2.126 One critical feature of systems relying on paid donation, compared with those that are totally voluntary, is the marked increase in the rate of post-transfusion hepatitis. Indeed, it was this phenomenon which led to the phasing out of paid blood donation in the U.S, and which played a critical role in Australian authorities deciding not to proceed with surrogate testing in the mid- to late-1980s.106

2.127 Many nations in Europe are self sufficient, but the UK has struck difficulty in maintaining supply of plasma, most recently due to the threat of Creutzfeldt-Jakob Disease being transmitted through the donor pool. As a result, the UK continues to rely on importation of American (paid) donations.107

The special case of haemophiliacs

2.128 Haemophilia is an inherited bleeding disorder which affects about one in 10,000 people. People with haemophilia do not bleed any faster than normal, but they do bleed longer, due to a deficiency in blood clotting factor. Depending on severity, haemophiliacs may bleed only after surgery, only after injury or dental work, or may bleed for no reason at all. In severe cases, bleeding can occur into muscles and joints, causing extreme pain.

---

103 Submission 74, p.21 (TBPAG). See also Committee Hansard 6.4.04 p.39 (TBPAG).
104 Senate, Hansard, Question No. 1781, 18.9.03, p.15651. There are no records indicating that Queensland ever collected blood from prisons Submission 64, Supplementary Information 9.6.04 (ARCBS).
105 Submission 64, p.63 (ARCBS). The United States operates dual collection systems; one for fresh blood and one for plasma.
106 Submission 64, pp.44,47,63 (ARCBS).
107 Submission 64, p.63 (ARCBS).
2.129 Haemophilia A is the most common form of haemophilia and is due to a deficiency of Factor VIII. Haemophilia B is due to a deficiency of Factor IX. The amount of Factor VIII or Factor IX transfused each year is dependent on the severity of the haemophilia and frequency of bleeding. Von Willebrand disorder is another inherited bleeding disorder. Treatment includes infusions of a clotting factor concentrate that contains von Willebrand factor.

2.130 Until 1964, haemophilia had been treated with blood plasma. In 1964, a concentration of Factor VIII by freeze thawing of plasma (known as cryoprecipitate) was developed. From the late 1970s, Factor VIII concentrate was made by CSL. A Factor IX concentrate called Prothrombinex was also developed by CSL. Prothrombinex was the major form of treatment of haemophilia B until it was replaced with a purer Factor IX concentrate (Monofix). The pooling of thousands of donations of plasma is used to manufacture Factor VIII and Factor IX concentrates.

2.131 The HFA noted that factor concentrates have revolutionised haemophilia treatment. They can be made from human blood (called plasma-derived products) or manufactured using genetically engineered cells that carry a human factor gene (recombinant products).

**Hepatitis C in the haemophilia community**

2.132 The HFA reported that following treatment with contaminated blood clotting factor concentrates, 85 to 90 per cent of people with haemophilia have been infected with hepatitis C. HFA went on to state that it is likely that up to 90 per cent of people with haemophilia A and haemophilia B developed NANBH with their first treatments of non-heat treated factor. There are also more than 250 people with haemophilia who were infected with HIV and many of these people are co-infected with HCV.

2.133 The HFA stated that many people with haemophilia in Australia were known to have hepatitis from the use of blood products and any symptoms they had 'were lived with'. Many did not experience any serious symptoms and the risks inherent in plasma pooling were balanced against the benefit of the utility of concentrates. Hepatitis was seen as an unfortunate consequence, but an acceptable risk of blood products. The HFA concluded that

[In reality, people with haemophilia had no choice of whether or not to use plasma products. When they have severely painful joint or a life threatening bleeding episode, the decision is clear to use the available treatment products, even if the treatment may have associated risks.] (HFA).

108 Submission 64, pp.58-59 (ARCBS).
109 Submission 82, p.3 (HFA).
110 Submission 82, p.5 (HFA).
111 Submission 82, p.8 (HFA).
2.134 The very high prevalence of hepatitis C among people living with haemophilia can be ascribed to the following three factors:

- the inability to inactivate virus present in plasma and cryoprecipitate;
- the inability to inactivate NANB hepatitis in pooled plasma products, prior to the early 1990s; and
- regular use of a number of blood products which were manufactured from a large number of donations.

2.135 In October/November 1984, CSL adopted a method of preparation of Factor VIII (used to treat haemophilia A) which allowed for the Factor to be pasteurised by heating at 60°C for 72 hours, thereby destroying some contaminating viruses eg HBV and HIV. Similar treatment was applied to Factor IX from January 1985.

2.136 The first limited supplies of super heat-treated Factor VIII (80°C for 72 hours) became available in January 1990, after reports from Europe of transmission occurring through Factor heated at the lower temperature.112

2.137 Prothrombinex concentrates were heat treated at 60°C for 72 hours from 1985 onward. Super heat-treated Factor IX concentrates (heating at 80°C for 72 hours, shown to inactivate HCV virus) did not become available in Australia until 1993.113

2.138 CSL acknowledged the risks associated with use of Factors VIII and IX prior to 1989 and 1992, adding that:

[W]ith hindsight…the hepatitis C virus—or Non-A, Non-B hepatitis as it was known then—was most probably present in every plasma pool throughout the seventies and the eighties…[i]t is unfortunate that scientific knowledge of hepatitis C was not sufficient early enough to prevent infection in the majority of severe haemophilia A and haemophilia B patients treated prior to the 1990s.114

2.139 CSL pointed out that the introduction of heat treatment was initially controversial. It was argued by some that such practices could lead to an increase in HAV and HBV positive people who developed inhibitors, a potentially life-threatening complication characterised by resistance to replacement therapy. There would also be a reduction in yield. However, the discovery that HIV was heat sensitive, could be inactivated at 60 degrees, and could otherwise be transmitted through transfusion, was persuasive.115

---

112 Confidential Submission 51, p.17.
113 Submission 64, pp.58-61 (ARCBS).
114 Committee Hansard 5.4.04, p.43 (CSL).
115 Committee Hansard 5.4.04, p.57 (CSL).
2.140 CSL went on to remind the Committee that, at the time most heat treatment was introduced, HCV was still not identified as being a single virus, and that it was not until the late 1980s that it became clear that 60 degree heat treatment was insufficient to inactivate the virus which, in 1990, came to be known as hepatitis C.\(^{116}\)

2.141 This delay was of concern to the HFA, who submitted that:

> There was a considerable delay before Prothrombinex [the Factor IX based product], heat treated to 80º C, was introduced in mid 1993. This caused frustration and anxiety for clinicians and patients. Some clinicians kept their patients on cryoprecipitate to minimise the risk of larger plasma pools. PTX heat treated to 60º was insufficient to inactivate hepatitis C.\(^{117}\)

2.142 The HFA also stated that Bio Products Laboratory in the United Kingdom had increased heat treatment factor VIII to 80 degrees, which prevented transmission of NANBH, in 1985. However, CSL did not replicate the process until 1989.\(^{118}\)

2.143 CSL pointed to the added difficulty of inactivating virus in Factor IX, saying that fortification against the 80 degree heat treatment necessitated a substantial reformulation of the product to guard against the occurrence of thrombosis in recipients.\(^{119}\)

2.144 The HFA and CSL both stated that there has been no known infection since additional heat treatment of Factor VIII concentrates in 1989 and Factor IX in 1993.\(^{120}\)

2.145 The use of recombinant Factor VIII and IX is discussed further in Chapter 6.

\(^{116}\) Committee Hansard 5.4.04, p.57 (CSL).

\(^{117}\) Submission 82, p.13 (HFA).

\(^{118}\) Committee Hansard 5.4.04, p.4 (HFA).

\(^{119}\) Confidential Submission 51, pp.28-29.

\(^{120}\) Submission 82, p.17 (HFA); Committee Hansard 5.4.04, p.53 (CSL).